Cargando…

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke

Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Stephanie, Dean, Judith, Gilks, Charles, Boyd, Mark A., Fitzgerald, Lisa, Mutch, Allyson, Baker, Peter, Neilsen, Graham, Gartner, Coral E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551237/
https://www.ncbi.nlm.nih.gov/pubmed/28718828
http://dx.doi.org/10.3390/ijerph14070799
_version_ 1783256274833506304
author Bell, Stephanie
Dean, Judith
Gilks, Charles
Boyd, Mark A.
Fitzgerald, Lisa
Mutch, Allyson
Baker, Peter
Neilsen, Graham
Gartner, Coral E.
author_facet Bell, Stephanie
Dean, Judith
Gilks, Charles
Boyd, Mark A.
Fitzgerald, Lisa
Mutch, Allyson
Baker, Peter
Neilsen, Graham
Gartner, Coral E.
author_sort Bell, Stephanie
collection PubMed
description Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations.
format Online
Article
Text
id pubmed-5551237
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55512372017-08-11 Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke Bell, Stephanie Dean, Judith Gilks, Charles Boyd, Mark A. Fitzgerald, Lisa Mutch, Allyson Baker, Peter Neilsen, Graham Gartner, Coral E. Int J Environ Res Public Health Concept Paper Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations. MDPI 2017-07-18 2017-07 /pmc/articles/PMC5551237/ /pubmed/28718828 http://dx.doi.org/10.3390/ijerph14070799 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Concept Paper
Bell, Stephanie
Dean, Judith
Gilks, Charles
Boyd, Mark A.
Fitzgerald, Lisa
Mutch, Allyson
Baker, Peter
Neilsen, Graham
Gartner, Coral E.
Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke
title Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke
title_full Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke
title_fullStr Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke
title_full_unstemmed Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke
title_short Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke
title_sort tobacco harm reduction with vaporised nicotine (thrive): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with hiv who smoke
topic Concept Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551237/
https://www.ncbi.nlm.nih.gov/pubmed/28718828
http://dx.doi.org/10.3390/ijerph14070799
work_keys_str_mv AT bellstephanie tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT deanjudith tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT gilkscharles tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT boydmarka tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT fitzgeraldlisa tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT mutchallyson tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT bakerpeter tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT neilsengraham tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke
AT gartnercorale tobaccoharmreductionwithvaporisednicotinethrivethestudyprotocolofanuncontrolledfeasibilitystudyofnovelnicotinereplacementproductsamongpeoplelivingwithhivwhosmoke